References
1. Neffen H, Fritscher C, Schacht FC, Levy G, Chiarella P, Soriano JB, et al. Asthma control in Latin America: the Asthma Insights and Reality in Latin America (AIRLA) survey. Rev Panam Salud Publica. 2005;17(3):191-7.
2. Global Iniciative for Asthma Management and Prevention 2020 [Available from: www.ginaasthma.org .
3. Colciencias MdSyPS-. Guía de Práctica Clínica Para el diagnóstico, atención integral y seguimiento de niños y niñas con diagnóstico de Asma. Guía No. 01 2014 [Available from: ,http://gpc.minsalud.gov.co/gpc_sites/Repositorio/Conv_500/GPC_asma/GPC_Comp_Asma.pdf .
4. Silvestri M, Sabatini F, Spallarossa D, Fregonese L, Battistini E, Biraghi MG, et al. Exhaled nitric oxide levels in non-allergic and allergic mono- or polysensitised children with asthma. Thorax. 2001;56(11):857-62.
5. Strunk RC, Szefler SJ, Phillips BR, Zeiger RS, Chinchilli VM, Larsen G, et al. Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children. J Allergy Clin Immunol. 2003;112(5):883-92.
6. Petsky HL, Kew KM, Chang AB. Exhaled nitric oxide levels to guide treatment for children with asthma. Cochrane Database Syst Rev. 2016;11:CD011439.
7. Berg J, Lindgren P. Economic evaluation of FE(NO) measurement in diagnosis and 1-year management of asthma in Germany. Respir Med. 2008;102(2):219-31.
8. Sabatelli L, Seppala U, Sastre J, Crater G. Cost-effectiveness and Budget Impact of Routine Use of Fractional Exhaled Nitric Oxide Monitoring for the Management of Adult Asthma Patients in Spain. J Investig Allergol Clin Immunol. 2017;27(2):89-97.
9. Brooks EA, Massanari M. Cost-Effectiveness Analysis of Monitoring Fractional Exhaled Nitric Oxide (FeNO) in the Management of Asthma. Manag Care. 2018;27(7):42-8.
10. Harnan SE, Tappenden P, Essat M, Gomersall T, Minton J, Wong R, et al. Measurement of exhaled nitric oxide concentration in asthma: a systematic review and economic evaluation of NIOX MINO, NIOX VERO and NObreath. Health Technol Assess. 2015;19(82):1-330.
11. Ralston SL, Lieberthal AS, Meissner HC, Alverson BK, Baley JE, Gadomski AM, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014;134(5):e1474-502.
12. Morphew T, Shin HW, Marchese S, Pires-Barracosa N, Galant SP. Phenotypes favoring fractional exhaled nitric oxide discordance vs guideline-based uncontrolled asthma. Ann Allergy Asthma Immunol. 2019;123(2):193-200.
13. Rodriguez-Martinez CE, Sossa-Briceno MP, Castro-Rodriguez JA. Cost-utility analysis of the inhaled steroids available in a developing country for the management of pediatric patients with persistent asthma. J Asthma. 2013;50(4):410-8.
14. Estadisticas DAN. Índice de Precios al Consumidor - IPC 2020 [Available from:https://www.dane.gov.co/index.php/estadisticas-por-tema/precios-y-costos/indice-de-precios-al-consumidor-ipc
15. la Bd, Republica. Tasa Representativa del Mercado (TRM - Peso por dólar) 2019 [cited 2020. Available from:https://www.banrep.gov.co/es/estadisticas/trm.
16. Departamento, Nacional, (DANE) DE. Archivo Nacional de Datos 2019 [Available from:https://sitios.dane.gov.co/anda-index/.
17. Felli JC, Hazen GB. Sensitivity analysis and the expected value of perfect information. Med Decis Making. 1998;18(1):95-109.
18. Beerthuizen T, Voorend-van Bergen S, van den Hout WB, Vaessen-Verberne AA, Brackel HJ, Landstra AM, et al. Cost-effectiveness of FENO-based and web-based monitoring in paediatric asthma management: a randomised controlled trial. Thorax. 2016;71(7):607-13.
19. Price D, Berg J, Lindgren P. An economic evaluation of NIOX MINO airway inflammation monitor in the United Kingdom. Allergy. 2009;64(3):431-8.
20. Buendia JA. [Attitudes, knowledge and beliefs of patient about anti-hypertensive drugs]. Biomedica. 2012;32(4):578-84.